ABSTRACT
Objective:To study the effects of ganoderma lucidum A on the proliferation and apoptosis of human inflammatory breast cancer SUM149 cells in vitro,and to clarify their mechanisms.Methods:The human inflammatory breast cancer SUM149 cells were divided into control group and different concentrations (0.1,0.5,1.0,5.0 and 10.0 μmol · L-1) of ganoderma lucidum A groups;four holes were set up,and the samples were taken at 24,48 and 72 h after culture.MTT assay was used to detect the inhibitory rate of proliferation of SUM149 cells.Flow cytometry was used to detect the apoptotic rate and cell cycle of SUM149 cells.The expression levels of Ki67 and Livin proteins in SUM149 cells were detected by immunocytochemical staining.Results:Compared with 0.1 μmol · L-1 ganoderma lucidum A group,the inhibitory rates of proliferation of SUM149 cells in other concentrations of ganoderma lucidum A groups were significantly increased detectde by MTTmethod (P＜0.05 or P＜0.01) in a concentration-and time-dependent manner.The flow cytometry results showed that the apoptotic rates of SUM149 cells in different conventrations of ganoderma lucidum A groups were significantly higher than that in control group (P＜ 0.05 or P＜ 0.01) in a concentration-and time-dependent manner;at the same time,the cell cycle changed significantly.With the increase of ganoderma lucidum A of the concentration of ganoderma lucidum A,the pencentages of cells at G1 phase in different concentrations of ganoderma lucidum A groups were increased (P＜0.05),and the percentages of cells at S phase were decreased compared with control group (P＜0.05 or P＜0.01).The expression levels of Ki67 and Livin proteins in different concentrations of ganoderma lucidum A groups were decreased compared with control group (P＜0.05).Conclusion:Ganoderma lucidum A can inhibit the proliferation of human inflammatory breast cancer SUM149 cells through induction of apoptosis.
ABSTRACT
Objective: To study the effects of ganoderma lucidum A on the proliferation and apoptosis of human inflammatory breast cancer SUM149 cells in vitro, and to clarify their mechanisms. Methods: The human inflammatory breast cancer SUM149 cells were divided into control group and different concentrations (0. 1, 0. 5, 1.0, 5. 0 and 10. 0 μmol · L-1) of ganoderma lucidum A groups; four holes were set up, and the samples were taken at 24, 48 and 72 h after culture. MTT assay was used to detect the inhibitory rate of proliferation of SUM149 cells. Flow cytometry was used to detect the apoptotic rate and cell cycle of SUM149 cells. The expression levels of Ki67 and Livin proteins in SUM149 cells were detected by immunocytochemical staining. Results: Compared with 0. 1 μmol · L-1 ganoderma lucidum A group, the inhibitory rates of proliferation of SUM149 cells in other concentrations of ganoderma lucidum A groups were significantly increased detectde by MTT method (P<0. 05 or P<0. 01) in a concentration- and time-dependent manner. The flow cytometry results showed that the apoptotic rates of SUM149 cells in different conventrations of ganoderma lucidum A groups were significantly higher than that in control group (P<0. 05 or P<0. 01) in a concentration- and time-dependent manner; at the same time, the cell cycle changed significantly. With the increase of ganoderma lucidum A of the concentration of ganoderma lucidum A, the pencentages of cells at G1 phase in different concentrations of ganoderma lucidum A groups were increased (P<0. 05), and the percentages of cells at S phase were decreased compared with control group (P<0. 05 or P<0. 01). The expression levels of Ki67 and Livin proteins in different concentrations of ganoderma lucidum A groups were decreased compared with control group (P<0. 05). Conclusion: Ganoderma lucidum A can inhibit the proliferation of human inflammatory breast cancer SUM149 cells through induction of apoptosis.
ABSTRACT
Objective: To investigate the relationship of clinicopathological characteristics with neoadjuvant chemotherapeutic efficacy and prognosis of inflammatory breast cancer (IBC) patients. Methods: Medical records of 81 patients who underwent neoadjuvant chemotherapy for IBC in Tianjin Medical University Cancer Institute and Hospital between January 2010 and December 2013, were retrospectively analyzed. Clinicopathological features, response to neoadjuvant chemotherapy, and prognostic factors were studied by univariate and multivariate analyses. Results: The 3-year overall survival rate (OS) and disease-free survival rate (DFS) of patients were 53.1％ and 37.0％, respectively. The pathologic complete response (pCR) rate of patients after accepting neoadjuvant chemotherapy was 13.6％ (11/81). Statistically significant association was observed between pCR and pathological types in IBC (P0.05). Preoperative lymph node stage was an independent prognostic factor of overall survival (OS) and disease- free survival (DFS) in IBC patients (P<0.05). Neoadjuvant chemotherapy and lymph vessel tumor emboli were independent factors of DFS (all P<0.05). Conclusion: Clinicopathological characteristics of IBC patients affected chemosensitivity. We could predict the prognosis of these patients by preoperative lymph node stage and lymph vessel tumor emboli and select chemotherapy to achieve the best curative effect.
ABSTRACT
Objective To explore the relationship of molecular biology characteristic and the treatment outcome,and influence factors of neoadjuvant chemotherapy (NAC) in inflammatory breast cancer (IBC).Methods The clinicopathological data of 103 IBC patients who were treated with NAC from January 2005 to June 2013 were analyzed retrospectively.Immunohistochemical method was used to detect the expression of estrogen receptor (ER),progesteron receptor (PR),human epidermal growth factor receptor 2 (HER-2) and E-cadherin.The treatment outcome were evaluated.Results In 103 IBC patients,ER negative was 48 patients,PR negative was 51 patients,HER-2 positive was 45 patients,E-cadherin positive was 66 patients.The effective rate of chemotherapy was 72.8％ (75/103).The effective rate of chemotherapy in taxane-based group was significantly higher than that in anthracycline-based group [80.6％ (50/62) vs.61.0％(25/41)],and there was significant difference (P ＜ 0.05).The effective rate of chemotherapy in ER,PR,E-cadherin negative patients was significantly higher than that in ER,PR,E-cadherin positive patients [83.3％ (40/48) vs.63.6％ (35/55),82.4％ (42/51) vs.63.5％ (33/52),83.8％ (31/37) vs.66.7％ (44/66)],and there was significant difference (P ＜ 0.05).The effective rate of chemotherapy in taxane-based group with E-cadherin positive patients was significantly higher than that in anthracycline-based group with E-cadherin positive patients [77.5％ (31/40) vs.50.0％ (13/26)] (P ＜0.05).No correlation existed between the expression of HER-2 and the treatment outcome of chemotherapy (P ＞ 0.05).Conclusion ER,PR and E-cadherin negative patients with IBC is chemosensitive to NAC.The positive expression of E-cadherin may be an important factor of chemotherapy resistance.For the patients with E-cadherin positive,taxane-based chemotherapy regimen can achieve a better effective rate.
ABSTRACT
El cáncer de mama inflamatorio es una patología poco frecuente, sin embargo, su importancia radica en la agresividad de su evolución. A nivel nacional no existe estadística certera respecto al porcentaje del cáncer inflamatorio de mama como tal. En el Hospital Base de Valdivia, constituye el 3,3 por ciento de los carcinomas mamarios invasores según una revisión de los últimos 3 años. El diagnóstico de esta patología está basado en la sospecha clínica, en pacientes que presenten eritema, edema, piel de naranja, nódulos y/o induración mamaria. La histopatología del tumor primario y de la piel permite la confirmación diagnóstica. En cuanto al tratamiento, en la actualidad existe consenso de que las pacientes deben ser sometidas a un tratamiento multimodal, éste consiste en quimioterapia neoadyuvante, para luego efectuar la terapia locorregional. Lo particular de este tipo de cáncer, es que posee características biológicas intrínsecas de rápida progresión y alto poder de diseminación, lo que le confiere un mal pronóstico.
Inflammatory breast cancer is a rare disease, but its importance lies in the aggressiveness of its evolution. At the national level there is no accurate statistics on the percentage of inflammatory breast cancer as such. In the Base Hospital of Valdivia, constitute 3.3 percent of invasive breast carcinomas according to a review of the past 3 years. The diagnosis of this disease is based on clinical suspicion in patients presenting with erythema, edema, cellulitis, nodules, and / or breast induration. The histopathology of the primary tumor and skin allows diagnostic confirmation. As for treatment, there is now consensus that patients should be subjected to a multimodal treatment, starting with neoadjuvant chemotherapy and then perform locoregional therapy. The particularity of this type of cancer is that it has intrinsic biological characteristics of rapid progression and high power spread, which gives a poor prognosis.